While adaptive biotechnologies shareholders are down 28% for the year, the market itself is up 33%. Adpt) is owned by 82.67% institutional shareholders, 59.01% adaptive biotechnologies corp insiders, and 0.00% retail investors.
Insiders of adaptive biotechnologies corporation (nasdaq:adpt) must have made a tidy sum after selling stock currently worth us$35.34 at us$39.64.
Adaptive biotechnologies stock buy or sell. Adpt ) stock is to hold adpt stock. Jyoti palaniappan has not been actively trading shares of adaptive biotechnologies over the course of the past ninety days. Is adaptive biotechnologies corp stock a good buy in 2021, according to wall street analysts?
Engages in the development of an immune medicine platform. The last three months saw some adaptive biotechnologies insider selling. Out of 2 analysts, 0 ( 0% ) are recommending adpt as a strong buy, 0 ( 0% ) are recommending adpt as a buy, 2 ( 100% ) are recommending adpt as a hold, 0 ( 0% ) are.
Use the zacks rank and style scores to find out is adpt is right for your portfolio. Should i buy adaptive biotechnologies (adpt)? Beta is a measure of a share's volatility in relation to the market.
The market (nasdaq average) beta is 1, while adaptive biotechnologies corporation's is 0.2777. A popular way to gauge a stock's volatility is its beta. Global performance llc viking is the largest individual adaptive biotechnologies corp shareholder, owning 30.99m shares representing 21.96% of the company.
The consensus among 2 wall street analysts covering ( nasdaq : If you are thinking of buying or selling adaptive biotechnologies stock, you should check out this free detailed report on its balance sheet. Adaptive biotechnologies (adpt) could be a solid addition to your portfolio given its recent upgrade to a zacks rank #2 (buy).
While we wait, check out this free list of growing companies with considerable, recent, insider buying. Insiders at adaptive biotechnologies have sold stock recently. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
Adaptive biotechnologies (adpt) has been upgraded to a zacks rank #2 (buy), reflecting growing optimism about the company's earnings prospects. Specifically, they have bought $0.00 in company stock and sold $2,156,559.00 in company stock. Most recently, jyoti palaniappan sold 651 shares of the business's stock in a transaction on monday, july 19th.
Its products and services include immunoseq, clonoseq, cellular therapy, and vaccines. Adaptive biotechnologies shares (adpt) are listed on the nasdaq and all prices are listed in us dollars. For the last reported quarter, it was expected that adaptive biotechnologies would post a loss of $0.43 per share when it actually produced a.
Adaptive biotechnologies currently has 2 hold ratings and 3 buy ratings from wall street analysts. I will like adaptive biotechnologies better if i see some big insider buys. The company was founded by chad robins, harlan robins,.
A popular way to gauge a stock's volatility is its beta. This might drive the stock higher in the near term. In the past three months, adaptive biotechnologies insiders have sold more of their company's stock than they have bought.
View the latest ratings for adpt. Is it worth investing in adaptive biotechnologies corporation (nasdaq :adpt) right now? The stock has a consensus analyst rating of buy. a buy rating indicates that analysts believe adpt will outperform the market and that investors should add to their positions of adaptive biotechnologies.
The market (nasdaq average) beta is 1, while adaptive biotechnologies corporation's is. According to the issued ratings of 5 analysts in the last year, the consensus rating for adaptive biotechnologies stock is buy based on the current 2 hold ratings and 3 buy ratings for adpt. Unlike other cell types, which operate on a fixed set of code from the human genome, immune.
Over the last 12 months, adaptive biotechnologies corporation's shares have ranged in value from as little as $29.735 up to $71.25. Beta is a measure of a share's volatility in relation to the market. Over the last 12 months, adaptive biotechnologies corporation's shares have ranged in value from as little as $27.33 up to $71.25.
Despite the fact that adaptive biotechnologies. The shares were sold at an average price of $36.12, for a transaction totalling $23,514.12. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for adaptive biotechnologies corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
